Article Text

PDF
THU0273 Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after one year of treatment with etanercept - results of the esther trial
  1. I.-H. Song1,
  2. K.-G. Hermann2,
  3. H. Haibel1,
  4. C. Althoff2,
  5. D. Poddubnyy1,
  6. J. Listing3,
  7. A. Weiß3,
  8. E. Lange4,
  9. B. Freundlich5,
  10. M. Rudwaleit6,
  11. J. Sieper1
  1. 1Medical Clinic I/Rheumatology, Charite Campus Benjamin-Franklin
  2. 2Radiology, Charite Mitte
  3. 3Statistics, German Rheumatism Research Center
  4. 4Pfizer, Berlin, Germany
  5. 5Rheumatology, University of Pennsylvania, Philadelphia, United States
  6. 6Private Practice, Endokrinologikum, Berlin, Germany

Abstract

Objectives In patients with early axial spondyloarthritis (SpA) with a disease duration of <5 years and with active inflammation on whole-body magnetic resonance imaging (wb-MRI) in the spine and/or sacroiliac joints (SIJ) at baseline we assessed whether there is a better response to etanercept (ETA) treatment in patients with ankylosing spondylitis (AS) compared to patients with non-radiographic axial SpA (nr-axSpA) [1].

Methods In the previously reported ESTHER trial axial SpA patients (nr-ax SpA, n=20; AS, n=20) were treated over 1 year with ETA [1]. Efficacy data on clinical, laboratory and magnetic resonance imaging of sacroliac joints (SI-joints) and spine response were analysed separately for patients with AS and nr-axSpA [2].

Results At baseline there were no differences between the 20 AS patients and the 20 nr-ax SpA patients regarding age (34.8 (SD 8.2) vs. 34.3 (SD 9.1) years), gender (60.0% vs. 55.0% male), HLA-B27 positivity (90.0% vs. 80.0%), respectively, and parameters of disease activity at baseline (Table 1). Only the MRI-scores were slightly but non-significantly higher in the AS-group. After 48 weeks of treatment with ETA there was a small though non-significant advantage in favor of the nr-axSpA group in nearly all outcome variables (Table 1).

Table 1. Comparison of efficacy parameters between patients with AS and nr-ax SpA, Data at week 48 (W48) compared to baseline (BL)

Conclusions There was a similar response in early axial SpA patients treated with ETA, independently whether they belonged to the group of nr-axSpA or AS, with even a slightly better response for nr-axSpA patients. Regarding response rates, short symptom duration seems to matter more than presence or absence of (radiographic) damage.

  1. Song I.-H. et al. 2011. Ann Rheum Dis. 2011;70(7):1257-63.

  2. Rudwaleit M. et al. 2009. Ann Rheum Dis. 2009 Jun;68(6):777-83.

Disclosure of Interest I.-H. Song Speakers Bureau: Pfizer/Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals: consulting fees or other remuneration. K.-G. Hermann: None Declared, H. Haibel Speakers Bureau: Pfizer/Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals: consulting fees or other remuneration. C. Althoff: None Declared, D. Poddubnyy Speakers Bureau: Pfizer/Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals: consulting fees or other remuneration. J. Listing: None Declared, A. Weiß: None Declared, E. Lange Employee of: Pfizer Germany, B. Freundlich Employee of: former employee from Pfizer/Wyeth, M. Rudwaleit Speakers Bureau: Pfizer/ Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals, UCB: consulting fees or other remuneration. J. Sieper Grant/Research support from: Study supported with unrestricted grant from Pfizer/Wyeth, Speakers Bureau: Pfizer/Wyeth Pharmaceuticals, Merck Sharp Dohme/Schering Plough, Abbott Immunology Pharmaceuticals, UCB: consulting fees or other remuneration.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.